Thomas Winder

4.0k total citations
108 papers, 2.1k citations indexed

About

Thomas Winder is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas Winder has authored 108 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 40 papers in Molecular Biology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas Winder's work include Muscle Physiology and Disorders (18 papers), Colorectal Cancer Treatments and Studies (14 papers) and Cancer Genomics and Diagnostics (13 papers). Thomas Winder is often cited by papers focused on Muscle Physiology and Disorders (18 papers), Colorectal Cancer Treatments and Studies (14 papers) and Cancer Genomics and Diagnostics (13 papers). Thomas Winder collaborates with scholars based in United States, Austria and Switzerland. Thomas Winder's co-authors include Heinz‐Josef Lenz, Dongyun Yang, Armin Gerger, Margherita Milone, Kathleen M. Jacobson, Robert W. Baloh, Axel Muendlein, Georg Lurje, Steven A. Moore and Pierre Bohanes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Thomas Winder

102 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Winder United States	28	916	519	435	435	318	108	2.1k
Maya Lodish United States	34	1.0k 1.1×	505 1.0×	1.5k 3.5×	418 1.0×	264 0.8×	130	3.9k
Susan Russell United States	26	550 0.6×	260 0.5×	403 0.9×	538 1.2×	286 0.9×	47	2.6k
Ivana Kholová Finland	26	1.0k 1.1×	906 1.7×	775 1.8×	171 0.4×	410 1.3×	121	2.6k
David Ng United States	22	924 1.0×	275 0.5×	196 0.5×	230 0.5×	127 0.4×	45	1.9k
Alexander Schmeißer Germany	27	847 0.9×	290 0.6×	448 1.0×	487 1.1×	865 2.7×	94	2.5k
Amit Saxena United States	29	700 0.8×	324 0.6×	442 1.0×	225 0.5×	1.1k 3.4×	97	3.5k
Max M. van Noesel Netherlands	27	831 0.9×	541 1.0×	321 0.7×	598 1.4×	86 0.3×	83	2.3k
Brian T. Nowlin United States	10	977 1.1×	153 0.3×	377 0.9×	434 1.0×	95 0.3×	11	2.2k
Atsuhiro Kawashima Japan	26	886 1.0×	747 1.4×	1.2k 2.9×	614 1.4×	102 0.3×	100	3.0k
David Walterhouse United States	33	1.7k 1.9×	678 1.3×	622 1.4×	1.2k 2.8×	99 0.3×	91	3.2k

Countries citing papers authored by Thomas Winder

Since Specialization

Citations

This map shows the geographic impact of Thomas Winder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Winder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Winder more than expected).

Fields of papers citing papers by Thomas Winder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Winder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Winder. The network helps show where Thomas Winder may publish in the future.

Co-authorship network of co-authors of Thomas Winder

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Winder. A scholar is included among the top collaborators of Thomas Winder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Winder. Thomas Winder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seeber, Andreas, Bernhard Doleschal, Hossein Taghizadeh, et al.. (2024). 530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study. Annals of Oncology. 35. S445–S446.

Stintzing, Sebastian, Jan Wierecky, Axel Wein, et al.. (2024). Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC.. Journal of Clinical Oncology. 42(16_suppl). 3551–3551. 1 indexed citations

Lehmann, Kuno, et al.. (2023). What have we learnt from the past – would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?. BMC Cancer. 23(1). 148–148. 2 indexed citations

Heymach, John V., David H. Harpole, Tetsuya Mitsudomi, et al.. (2023). Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research. 83(8_Supplement). CT005–CT005. 55 indexed citations

Stintzing, Sebastian, Jan Wierecky, Helmut Forstbauer, et al.. (2023). Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study.. Journal of Clinical Oncology. 41(4_suppl). 34–34. 1 indexed citations

Muendlein, Axel, Kathrin Geiger, Christine Heinzle, et al.. (2023). Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients. Journal of Cancer Research and Clinical Oncology. 149(9). 6435–6444. 5 indexed citations

Reck, Martin, Daniel P. Gale, David H. Harpole, et al.. (2023). LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Annals of Oncology. 34. S1300–S1300. 23 indexed citations

Hoefle, Guenter, Matthias Frick, Alois Suessenbacher, et al.. (2023). Evaluation of SARS‐CoV‐2 antibody levels on hospital admission as a correlate of protection against mortality. Journal of Internal Medicine. 293(6). 694–703. 13 indexed citations

Wöll, Ewald, Arno Amann, Wolfgang Eisterer, et al.. (2023). Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update. Anticancer Research. 43(7). 2889–2897. 2 indexed citations

10.

Muendlein, Axel, Thomas Winder, Peter Fraunberger, et al.. (2022). SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study. BMJ Open. 12(5). e052130–e052130. 2 indexed citations

11.

Siebenhüner, Alexander, Sara De Dosso, Daniel Helbling, et al.. (2021). Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article. Oncology Research and Treatment. 44(9). 485–494. 21 indexed citations

12.

Muendlein, Axel, Kathrin Geiger, Tobias Dechow, et al.. (2021). Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. Scientific Reports. 11(1). 6761–6761. 17 indexed citations

13.

Stintzing, Sebastian, G Hübner, Jörg Schröder, et al.. (2021). P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC. Annals of Oncology. 32. S116–S116.

14.

Richtig, Georg, Ariane Aigelsreiter, Daniela Schwarzenbacher, et al.. (2017). SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS ONE. 12(11). e0187814–e0187814. 46 indexed citations

15.

Ning, Yan, Armin Gerger, Wu Zhang, et al.. (2013). Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. Molecular Cancer Therapeutics. 13(2). 528–539. 34 indexed citations

16.

Absenger, Gudrun, Joanna Szkandera, Michael Stotz, et al.. (2013). A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early‐stage breast cancer. Molecular Carcinogenesis. 52(S1). 96–102. 12 indexed citations

17.

Winder, Thomas, Georgios Giamas, P. M. Wilson, et al.. (2013). Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. The Pharmacogenomics Journal. 14(1). 28–34. 30 indexed citations

18.

Solomon, Benjamin D., Nancy J. Clegg, Mauricio R. Delgado, et al.. (2011). Holoprosencephaly in a family segregating novel variants in ZIC2 and GLI2. American Journal of Medical Genetics Part A. 155(4). 860–864. 11 indexed citations

19.

Winder, Thomas, Pierre Bohanes, Dongyun Yang, et al.. (2011). GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. Annals of Oncology. 22(11). 2431–2439. 26 indexed citations

20.

Muendlein, Axel, Christoph H. Saely, Thomas Winder, et al.. (2009). Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. Atherosclerosis. 206(2). 494–499. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact